Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 3Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 249Other hematologic neoplasm 135Plasma cell 10Myeloid 6Genitourinary 4Gastrointestinal 4CNS 4Thoracic 3Classical hematology 3Tumor-Agnostic 2Dermatologic 2Breast 2NET 1Head & Neck 1Endocrine 1

Conditions

Carcinoma, Renal Cell 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × ibrutinib × Genitourinary × Clear all
NCT06788509 2026-05-08

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT02899078 2025-05-18

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

University of California, Davis

Phase 1/2 Completed
31 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT02643667 2025-01-08

Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Washington University School of Medicine

Phase 2 Completed
27 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
263 enrolled 34 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡